Related Experiment Video
Updated: Aug 14, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Inhibition of ribosome assembly factor PNO1 by CRISPR/Cas9 technique suppresses lung adenocarcinoma and Notch
Sanjit K Roy1,2, Shivam Srivastava3, Andrew Hancock4
1Louisiana State University Health-New Orleans, School of Medicine, Stanley S. Scott Cancer Center, New Orleans, Louisiana, USA.
Abstract:
Growth is crucially controlled by the functional ribosomes available in cells. To meet the enhanced energy demand, cancer cells re-wire and increase their ribosome biogenesis. The RNA-binding protein PNO1, a ribosome assembly factor, plays an essential role in ribosome biogenesis. The purpose of this study was to examine whether PNO1 can be used as a biomarker for lung adenocarcinoma and also examine the molecular mechanisms by which PNO1 knockdown by CRISPR/Cas9 inhibited growth and epithelial-mesenchymal transition (EMT). The expression of PNO1 was significantly higher in lung adenocarcinoma compared to normal lung tissues. PNO1 expression in lung adenocarcinoma patients increased with stage, nodal metastasis, and smoking. Lung adenocarcinoma tissues from males expressed higher PNO1 than those from females. Furthermore, lung adenocarcinoma tissues with mutant Tp53 expressed higher PNO1 than those with wild-type Tp53, suggesting the influence of Tp53 status on PNO1 expression. PNO1 knockdown inhibited cell viability, colony formation, and EMT, and induced apoptosis. Since dysregulated signalling through the Notch receptors promotes lung adenocarcinoma, we measured the effects of PNO1 inhibition on the Notch pathway. PNO1 knockdown inhibited Notch signalling by suppressing the expression of Notch receptors, their ligands, and downstream targets. PNO1 knockdown also suppressed CCND1, p21, PTGS-2, IL-1α, IL-8, and CXCL-8 genes. Overall, our data suggest that PNO1 can be used as a diagnostic biomarker, and also can be an attractive therapeutic target for the treatment of lung adenocarcinoma.
Insights
The RNA-binding protein PNO1 is elevated in lung adenocarcinoma and linked to disease progression. Inhibiting PNO1 suppressed tumor growth, metastasis, and Notch signaling, suggesting PNO1 as a potential biomarker and therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Cellular growth relies on functional ribosomes, and cancer cells upregulate ribosome biogenesis to meet energy demands.
- The RNA-binding protein PNO1 is a key factor in ribosome assembly.
- Lung adenocarcinoma is a significant health concern, necessitating new diagnostic and therapeutic strategies.
Purpose of the Study:
- To investigate PNO1 as a potential biomarker for lung adenocarcinoma.
- To explore the molecular mechanisms by which PNO1 knockdown affects lung adenocarcinoma growth and epithelial-mesenchymal transition (EMT).
Main Methods:
- Quantitative analysis of PNO1 expression in lung adenocarcinoma tissues versus normal tissues.
- CRISPR/Cas9-mediated PNO1 knockdown to assess its impact on cell viability, colony formation, apoptosis, and EMT.
- Analysis of PNO1 knockdown effects on the Notch signaling pathway and related gene expression.
Main Results:
- PNO1 expression was significantly higher in lung adenocarcinoma tissues and correlated with advanced stage, nodal metastasis, smoking history, male sex, and Tp53 mutation status.
- PNO1 knockdown inhibited cell viability, colony formation, and EMT, while inducing apoptosis.
- PNO1 inhibition suppressed Notch signaling, including receptors, ligands, and downstream targets, as well as CCND1, p21, PTGS-2, IL-1α, IL-8, and CXCL-8 genes.
Conclusions:
- PNO1 is upregulated in lung adenocarcinoma and associated with adverse prognostic factors.
- PNO1 plays a crucial role in promoting lung adenocarcinoma growth, EMT, and Notch signaling.
- PNO1 represents a promising diagnostic biomarker and a potential therapeutic target for lung adenocarcinoma.
More Related Videos
10:21Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
Published on: January 5, 2018
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Related Concept Videos
Experimental RNAi
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
CRISPR/Cas9 Genome Editing
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
The Nucleolus